News J&J's Rybrevant Faspro moves beyond lung cancer with FDA nod The FDA has approved Johnson & Johnson's Rybrevant Faspro for head and neck cancer, extending the franchise beyond lung cancer for the first time.
News UK backs start-up Potential Sciences' AI-powered drug hunt UK start-up Potential Sciences emerged from stealth today with a sizeable seed funding round and an ambition to transform drug discovery with AI.
News Bayer's Hyrnuo moves first-line for lung cancer in China Bayer's oral HER2 inhibitor Hyrnuo has been approved in China as a frontline therapy for advanced, HER2-mutant non-small cell lung cancer.
News UK biotechs T-Therapeutics and Alethio score big financings Two up-and-coming UK biotechs – T-Therapeutics and Alethio Therapeutics – have raised $133m and $90m, respectively, in impressive financing rounds.
News NICE backs Keytruda/Padcev combo for bladder cancer Patients with muscle-invasive bladder cancer can now receive NHS treatment with MSD's Keytruda and Astellas' Padcev, given before and after surgery.
News Boehringer forges $7bn alliance with China's SBP Group Boehringer Ingelheim is paying $358m upfront for options on up to six antibody-drug conjugates and T-cell engagers from China's Sino Biopharma.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.